Literature DB >> 12627748

The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension.

Makoto Katori1, Masataka Majima.   

Abstract

The distal tubules of the kidney express the full set of the components of the kallikrein-kinin system, which works independently from the plasma kallikrein-kinin system. Studies on the role of the renal kallikrein-kinin system, using congenitally kininogen-deficient Brown-Norway Katholiek rats and also bradykinin B2 receptor knockout mice, revealed that this system starts to function and to induce natriuresis and diuresis when sodium accumulates in the body as a result of excess sodium intake or aldosterone release, for example, by angiotensin II. Thus, it can be hypothesized that the system works as a safety valve for sodium accumulation. The large numbers of studies on hypertensive animal models and on essential hypertensive patients, particularly those with salt sensitivity, indicate a tendency toward the reduced excretion of urinary kallikrein, although this reduction is modified by potassium intake and impaired renal function. We hypothesize that the reduced excretion of the renal kallikrein may be attributable to a genetic defect of factor(s) in renal kallikrein secretion process and may cause salt-sensitive hypertension after salt intake.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627748     DOI: 10.1080/713609329

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  12 in total

1.  Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans.

Authors:  Michel Azizi; Pierre Boutouyrie; Alvine Bissery; Mohsen Agharazii; Francis Verbeke; Nora Stern; Alessandra Bura-Rivière; Stéphane Laurent; François Alhenc-Gelas; Xavier Jeunemaitre
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

2.  Urine Potassium Excretion, Kidney Failure, and Mortality in CKD.

Authors:  Amanda K Leonberg-Yoo; Hocine Tighiouart; Andrew S Levey; Gerald J Beck; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2016-05-24       Impact factor: 8.860

Review 3.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

Review 4.  Hypertension and the bradykinin system.

Authors:  Jagdish N Sharma
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

5.  Ontogeny of bradykinin B1 receptors in the mouse kidney.

Authors:  Ozlem Pinar Bulut; Susana Dipp; Samir El-Dahr
Journal:  Pediatr Res       Date:  2009-11       Impact factor: 3.756

Review 6.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07

Review 7.  The Renin-Angiotensin System in the Development of Salt-Sensitive Hypertension in Animal Models and Humans.

Authors:  Beate Rassler
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-29

8.  Renal outcomes and dietary potassium: the overshadowed electrolyte?

Authors:  Kristen L Jablonski; Jessica B Kendrick
Journal:  Kidney Int       Date:  2014-12       Impact factor: 10.612

9.  Quantitative Serum Proteomic Analysis of Essential Hypertension Using iTRAQ Technique.

Authors:  Jing-Wen Xu; Yun-Lun Li; Shi-Jun Zhang; Wen-Qing Yang; Wen-Ting Nie; Hai-Qiang Jiang
Journal:  Biomed Res Int       Date:  2017-10-22       Impact factor: 3.411

10.  Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice.

Authors:  John J McGuire; Bruce N Van Vliet; Sarah J Halfyard
Journal:  BMC Physiol       Date:  2008-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.